Gilead Sciences 2Q Revenues: $1 billion (+53%) 2Q Earnings: $407.9 million (+54%) YTD Revenues: $2.1 billion (+51%) YTD Earnings: $815.3 million (+54%) Comments: Growth in the quarter was driven by HIV product sales, up 60% to $762.2 million. Atripla, launched in July 2006 in the U.S., achieved $212.4 million in sales. Truvada sales were $385.4 million, up 29%. Also contributing to growth in the quarter were Hepsera sales, up 32% to $75.2 million, and AmBisome sales, up 1...